title: HIV-1-Specific Chimeric Antigen Receptors Based on Broadly Neutralizing Antibodies.
abstract: Although the use of chimeric antigen receptors (CARs) based on single-chain antibodies for gene immunotherapy of cancers is increasing due to promising recent results, the earliest CAR therapeutic trials were done for HIV-1 infection in the late 1990s. This approach utilized a CAR based on human CD4 as a binding domain and was abandoned for a lack of efficacy. The growing number of HIV-1 broadly neutralizing antibodies (BNAbs) offers the opportunity to generate novel CARs that may be more active and revisit this modality for HIV-1 immunotherapy. We used sequences from seven well-defined BNAbs varying in binding sites and generated single-chain-antibody-based CARs. These CARs included 10E8, 3BNC117, PG9, PGT126, PGT128, VRC01, and X5. Each novel CAR exhibited conformationally relevant expression on the surface of transduced cells, mediated specific proliferation and killing in response to HIV-1-infected cells, and conferred potent antiviral activity (reduction of viral replication in log10 units) to transduced CD8(+) T lymphocytes. The antiviral activity of these CARs was reproducible but varied according to the strain of virus. These findings indicated that BNAbs are excellent candidates for developing novel CARs to consider for the immunotherapeutic treatment of HIV-1.
  
  
  
  While chimeric antigen receptors (CARs) using single-chain antibodies as binding domains are growing in popularity for gene immunotherapy of cancers, the earliest human trials of CARs were done for HIV-1 infection. However, those trials failed, and the approach was abandoned for HIV-1. The only tested CAR against HIV-1 was based on the use of CD4 as the binding domain. The growing availability of HIV-1 broadly neutralizing antibodies (BNAbs) affords the opportunity to revisit gene immunotherapy for HIV-1 using novel CARs based on single-chain antibodies. Here we construct and test a panel of seven novel CARs based on diverse BNAb types and show that all these CARs are functional against HIV-1.
authors.affiliation: Department of Medicine, Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California, USA.
authors.forename: Ayub
authors.initials: A
authors.lastname: Ali
authors.affiliation: Department of Medicine, Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California, USA.
authors.forename: Scott G
authors.initials: SG
authors.lastname: Kitchen
authors.affiliation: Department of Medicine, Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California, USA.|Department of Microbiology, Immunology, and Molecular Genetics, University of California, Los Angeles, Los Angeles, California, USA.
authors.forename: Irvin S Y
authors.initials: ISY
authors.lastname: Chen
authors.affiliation: Department of Medicine, Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California, USA.
authors.forename: Hwee L
authors.initials: HL
authors.lastname: Ng
authors.affiliation: Department of Medicine, Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California, USA.|Department of Microbiology, Immunology, and Molecular Genetics, University of California, Los Angeles, Los Angeles, California, USA.
authors.forename: Jerome A
authors.initials: JA
authors.lastname: Zack
authors.affiliation: Department of Medicine, Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California, USA oyang@mednet.ucla.edu.|Department of Microbiology, Immunology, and Molecular Genetics, University of California, Los Angeles, Los Angeles, California, USA.|AIDS Healthcare Foundation, Los Angeles, California, USA.
authors.forename: Otto O
authors.initials: OO
authors.lastname: Yang
mesh_terms: D000595:Amino Acid Sequence; D000911:Antibodies, Monoclonal / Q000276:immunology; D057134:Antibodies, Neutralizing / Q000276:immunology*; D015483:HIV Antibodies / Q000276:immunology*; D015658:HIV Infections / Q000276:immunology / Q000821:virology; D015497:HIV-1 / Q000276:immunology*; D006801:Humans; D019169:Jurkat Cells; D011946:Receptors, Antigen / Q000276:immunology*; D015728:Receptors, HIV / Q000276:immunology*; D017386:Sequence Homology, Amino Acid; D057127:Single-Chain Antibodies / Q000276:immunology; D013601:T-Lymphocytes / Q000276:immunology*
chemical_list: D000911:Antibodies, Monoclonal; D057134:Antibodies, Neutralizing; D015483:HIV Antibodies; D011946:Receptors, Antigen; D015728:Receptors, HIV; D057127:Single-Chain Antibodies